Home/ Stocks/ BHVN

Biohaven Ltd.

BHVN XNYS

$9.86 +0.09 (+0.92%) ▲ 15-min delayed

Open

$9.59

High

$9.92

Low

$9.36

Volume

1.98M

Market Cap

$1.48B

About Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 274 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-130,532,000	$-0.88
FY 2025	$0	$-738,822,000	$-6.86
Q3 2025	$0	$-173,443,000	$-1.64
Q2 2025	$0	$-198,147,000	$-1.94

Related Market News

No specific coverage for BHVN yet. Check out our latest market news or earnings calendar.

Get BHVN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Biohaven Ltd..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.